Tag: SBRT
-
Stereotactic Body Radiation Therapy in Inoperable PDAC: The TORPEDO Phase II Randomised Trial
Understanding the challenge of inoperable pancreatic cancer Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive solid tumors, with limited treatment options for patients whose disease is non-metastatic but inoperable. For these individuals, conventional treatment often focuses on systemic therapy and palliative care, aiming to control symptoms and extend survival without compromising quality of…
-
Stereotactic Body Radiation Therapy in Inoperable Pancreatic Cancer: Insights from the TORPEDO Phase II Randomised Trial
Overview: The TORPEDO Trial and the Challenge of PDAC Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, with many patients presenting with tumors that are inoperable or unsuitable for conventional curative surgery. In this context, the TORPEDO trial investigates the potential of stereotactic body radiation therapy (SBRT) as a treatment option to…
-
Stereotactic body radiation therapy and the TORPEDO trial: A new approach for inoperable pancreatic cancer
Overview: SBRT as a potential option for inoperable PDAC Pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging cancers to treat, especially when surgical options are off the table. For patients with non-metastasized yet inoperable disease, there is a critical need for effective, well-tolerated therapies. The TORPEDO trial investigates stereotactic body radiation therapy (SBRT)…
-
Lu-177 PNT2002 Combined with SBRT Delays Prostate Cancer Progression
Overview New data presented at the American Society for Radiation Oncology (ASTRO) meeting suggest that adding the radiopharmaceutical Lu-177 PNT2002 to stereotactic body radiation therapy (SBRT) can significantly delay disease progression in men with oligometastatic, or limited, prostate cancer. The LUNAR trial compared SBRT alone to a two-cycle course of Lu-177 PNT2002 followed by SBRT,…
-
Lu-177 PNT2002 Added to SBRT Delays Prostate Cancer Progression
New approach combines Lu-177 PNT2002 with SBRT In a pioneering study presented at the American Society for Radiation Oncology (ASTRO) meeting, researchers explored whether adding lutetium-177 (Lu-177) PNT2002 to stereotactic body radiation therapy (SBRT) could improve outcomes for men with oligometastatic, or limited, prostate cancer. The strategy targets occult micrometastases that often drive progression after…
-
Radiopharmaceutical Therapy Boosts Radiation, Slows Prostate Cancer
What the LUNAR trial tested SAN FRANCISCO, September 28, 2025 — A new phase II clinical trial, called LUNAR, shows that adding a radiopharmaceutical drug before high-precision radiation therapy can help people with a limited number of metastatic lesions from recurrent prostate cancer live longer without disease progression. In this randomized study, patients received either…
-
Radiopharmaceutical Therapy Boosts Radiation to Slow Prostate Cancer
New Findings from the LUNAR Trial A landmark phase II study, known as the LUNAR trial, reports that people with recurrent prostate cancer and a limited number of metastases lived significantly longer without disease progression when a radiopharmaceutical drug was given before targeted radiation therapy, compared with high-precision radiation alone. The randomized study evaluated whether…
-
Radiopharmaceutical Therapy Boosts Radiation in Prostate Cancer
LUNAR Trial: Combining Radiopharmaceutical Therapy with SBRT A phase II study known as the LUNAR trial investigated whether adding a PSMA-targeted radiopharmaceutical before high-precision radiation could improve outcomes for men with oligometastatic, hormone-sensitive recurrent prostate cancer. In this randomized study, 92 participants with one to five distant lesions visible on PSMA PET/CT were assigned to…